Phase I Clinical Trial of CVL218, a Novel PARP1/2 Inhibitor, in Patients with Advanced Solid Tumors

Abstract

CVL218, a novel poly ADP-ribose polymerase (PARP1/2) inhibitor, has strong PARP1/2 selective inhibitory activity and high oral bioavailability. We aimed to assess the safety and tolerability of CVL218 in patients with pretreated advanced solid tumors. Patients in this phase I dose escalation trial received one dose of CVL218 (50, 100, 200, 350, 500, 600, 700, and 850 mg) twice a day. The safety, tolerability, maximum tolerated dose (MTD), dose-limiting toxicity (DLT), recommended dose, as well as antitumor activity of CVL218 were evaluated. A total of 26 patients were enrolled in this trial. The most common treatment-related adverse events were vomiting (76.9%), nausea (76.9%), diarrhea (38.5%), proteinuria (23.1%), and lipase increased (23.1%). DLTs occurred in three patients, one out of six in the 700 mg BID group, and two out of five in the 850 mg BID group, so the MTD was set to 700 mg BID. Overall, the disease control rate (DCR) was 70.8%, while the DCR of patients with high-level doses (≥700 mg BID) and recommended dose (700 mg BID) were both 100%. CVL218 was generally well tolerated and safe. It showed potential antitumor activity in patients treated with the recommended dose.

Keywords

CVL218 / cancer / phase I / PARP / pharmacokinetics

References

[1] T. H. Kang, “DNA Damage, Repair, and Cancer Metabolism,” International Journal of Molecular Sciences 24, no. 22 (2023): 16430.

[2] R. Nagaraju, R. Kalahasthi, R. Balachandar, et al., “Cadmium Exposure and DNA Damage (genotoxicity): A Systematic Review and Meta-analysis,” Critical Reviews in Toxicology 52, no. 10 (2022): 786-798.

[3] E. Giudice, M. Gentile, V. Salutari, et al., “PARP Inhibitors Resistance: Mechanisms and Perspectives,” Cancers (Basel) 14, no. 6 (2022): 1420.

[4] N. J. Curtin and C. Szabo, “Poly(ADP-ribose) Polymerase Inhibition: Past, Present and Future,” Nature Reviews Drug Discovery 19, no. 10 (2020): 711-736.

[5] A. von Werdt, L. Brandt, O. D. Schärer, et al., “PARP Inhibition in Prostate Cancer with Homologous Recombination Repair Alterations,” JCO Precision Oncology 5 (2021). PO.21.00152. PMID: 34712892

[6] L. Nguyen, J. WMM, A. Van Hoeck, et al., “Pan-cancer Landscape of Homologous Recombination Deficiency,” Nature Communications 11, no. 1 (2020): 5584.

[7] N. Mekonnen, H. Yang, and Y. K. Shin, “Homologous Recombination Deficiency in Ovarian, Breast, Colorectal, Pancreatic, Non-Small Cell Lung and Prostate Cancers, and the Mechanisms of Resistance to PARP Inhibitors,” Frontiers in Oncology 12 (2022): 880643.

[8] R. Huang and P. K. Zhou, “DNA Damage Repair: Historical Perspectives, Mechanistic Pathways and Clinical Translation for Targeted Cancer Therapy,” Signal Transduction and Targeted Therapy 6, no. 1 (2021): 254.

[9] L. Perkhofer, J. Gout, E. Roger, et al., “DNA Damage Repair as a Target in Pancreatic Cancer: State-of-the-art and Future Perspectives,” Gut 70, no. 3 (2021): 606-617.

[10] D. Slade, “PARP and PARG Inhibitors in Cancer Treatment,” Genes & Development 34, no. 5-6 (2020): 360-394.

[11] J. Dias Nunes, I. Demeestere, and M. Devos, “BRCA Mutations and Fertility Preservation,” International Journal of Molecular Sciences 25, no. 1 (2023): 204.

[12] C. Shao, J. Wan, F. C. Lam, et al., “A Comprehensive Literature Review and Meta-analysis of the Prevalence of Pan-cancer BRCA Mutations, Homologous Recombination Repair Gene Mutations, and Homologous Recombination Deficiencies,” Environmental and Molecular Mutagenesis 63, no. 6 (2022): 308-316.

[13] M. Rose, J. T. Burgess, K. O'Byrne, et al., “PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance,” Frontiers in Cell and Developmental Biology 8 (2020): 564601.

[14] H. L. Kindler, P. Hammel, M. Reni, et al., “Overall Survival Results from the POLO Trial: A Phase III Study of Active Maintenance Olaparib versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer,” Journal of Clinical Oncology 40, no. 34 (2022): 3929-3939.

[15] J. de Bono, J. Mateo, K. Fizazi, “Olaparib for Metastatic Castration-Resistant Prostate Cancer,” New England Journal of Medicine 382, no. 22 (2020): 2091-2102.

[16] A. Poveda, A. Floquet, J. A. Ledermann, et al., “Olaparib Tablets as Maintenance Therapy in Patients With Platinum-sensitive Relapsed Ovarian Cancer and a BRCA1/2 Mutation (SOLO2/ENGOT-Ov21): A Final Analysis of a Double-blind, Randomised, Placebo-controlled, Phase 3 Trial,” The Lancet Oncology 22, no. 5 (2021): 620-631.

[17] P. DiSilvestro, S. Banerjee, N. Colombo, et al., “Overall Survival with Maintenance Olaparib at a 7-Year Follow-Up in Patients with Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial,” Journal of Clinical Oncology 41, no. 3 (2023): 609-617.

[18] J. X. He, M. Wang, X. J. Huan, et al., “Novel PARP1/2 Inhibitor Mefuparib Hydrochloride Elicits Potent in Vitro and in Vivo Anticancer Activity, Characteristic of High Tissue Distribution,” Oncotarget 8, no. 3 (2017): 4156-4168.

[19] X. M. Li, Y. D. Zheng, Y. F. Zhang, et al., “Absorption, Distribution, Metabolism, and Excretion of [(14)C]Mefuparib (CVL218), a Novel PARP1/2 Inhibitor, in Rats,” Cancer Chemotheraphy and Pharmacology 90, no. 6 (2022): 499-510.

[20] D. Dibitetto, C. A. Widmer, and S. Rottenberg, “PARPi, BRCA, and Gaps: Controversies and Future Research,” Trends in Cancer 10, no. 9 (2024): 857-869.

[21] A. Huang, L. A. Garraway, A. Ashworth, et al., “Synthetic Lethality as an Engine for Cancer Drug Target Discovery,” Nature Reviews Drug Discovery 19, no. 1 (2020): 23-38.

[22] L. Cortesi, H. S. Rugo, and C. Jackisch, “An Overview of PARP Inhibitors for the Treatment of Breast Cancer,” Targeted Oncology 16, no. 3 (2021): 255-282.

[23] Z. Cai, C. Liu, C. Chang, et al., “Comparative Safety and Tolerability of Approved PARP Inhibitors in Cancer: A Systematic Review and Network Meta-analysis,” Pharmacological Research 172 (2021): 105808.

[24] D. F. Wang, X. W. Shi, C. Zhang, et al., “Real-world Applications of PARPi Maintenance Therapy for Recurrent Ovarian Cancer: A Single-center Study in China,” Gynecologic Oncology 170 (2023): 25-31.

[25] X. H. Wu, J. Q. Zhu, R. T. Yin, et al., “Niraparib Maintenance Therapy in Patients With Platinum-sensitive Recurrent Ovarian Cancer Using an Individualized Starting Dose (NORA): A Randomized, Double-blind, Placebo-controlled Phase III Trial(☆),” Annals of Oncology 32, no. 4 (2021): 512-521.

[26] B. J. Monk, A. González-Martin, L. Buckley, et al., “Safety and Management of niraparib Monotherapy in Ovarian Cancer Clinical Trials,” International Journal of Gynecological Cancer 33, no. 6 (2023): 971-981.

[27] B. J. Monk, M. P. Barretina-Ginesta, B. Pothuri, et al., “Niraparib First-line Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer: Final Overall Survival Results From the PRIMA/ENGOT-OV26/GOG-3012 Trial,” Annals of Oncology 35, no. 11 (2024): 981-992.

[28] F. Trillsch, S. Mahner, B. Ataseven, et al., “Efficacy and Safety of olaparib According to Age in BRCA1/2-mutated Patients With Recurrent Platinum-sensitive Ovarian Cancer: Analysis of the Phase III SOLO2/ENGOT-Ov21 Study,” Gynecologic Oncology 165, no. 1 (2022): 40-48.

[29] P. M. Morice, A. Leary, C. Dolladille, et al., “Myelodysplastic Syndrome and Acute Myeloid Leukaemia in Patients Treated With PARP Inhibitors: A Safety Meta-analysis of Randomised Controlled Trials and a Retrospective Study of the WHO Pharmacovigilance Database,” The Lancet Haematology 8, no. 2 (2021): e122-e134.

[30] J. K. Overbeek, N. A. D. Guchelaar, M. I. Mohmaed Ali, et al., “Pharmacokinetic Boosting of olaparib: A Randomised, Cross-Over Study (PROACTIVE-study),” European Journal of Cancer 194 (2023): 113346.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.